SG Americas Securities LLC Grows Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

SG Americas Securities LLC lifted its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 48.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,070 shares of the company’s stock after purchasing an additional 5,906 shares during the quarter. SG Americas Securities LLC’s holdings in Phathom Pharmaceuticals were worth $165,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Invesco Ltd. grew its holdings in shares of Phathom Pharmaceuticals by 2.6% in the third quarter. Invesco Ltd. now owns 3,418,959 shares of the company’s stock valued at $35,455,000 after purchasing an additional 86,822 shares during the period. BlackRock Inc. grew its holdings in shares of Phathom Pharmaceuticals by 22.6% in the second quarter. BlackRock Inc. now owns 2,002,632 shares of the company’s stock valued at $28,678,000 after purchasing an additional 369,722 shares during the period. Vanguard Group Inc. grew its holdings in shares of Phathom Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 1,942,701 shares of the company’s stock valued at $26,441,000 after purchasing an additional 14,857 shares during the period. Kennedy Capital Management LLC grew its holdings in shares of Phathom Pharmaceuticals by 1.1% in the third quarter. Kennedy Capital Management LLC now owns 1,061,745 shares of the company’s stock valued at $11,010,000 after purchasing an additional 12,070 shares during the period. Finally, Woodline Partners LP purchased a new stake in shares of Phathom Pharmaceuticals in the second quarter valued at about $9,647,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Price Performance

Shares of PHAT opened at $10.02 on Tuesday. Phathom Pharmaceuticals, Inc. has a 1-year low of $6.07 and a 1-year high of $17.02. The stock has a market cap of $585.97 million, a PE ratio of -2.58 and a beta of 0.63. The firm has a 50-day simple moving average of $9.44 and a two-hundred day simple moving average of $8.74.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.12. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.93 million. During the same quarter in the prior year, the business earned ($1.33) earnings per share. As a group, sell-side analysts expect that Phathom Pharmaceuticals, Inc. will post -4.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Phathom Pharmaceuticals

In other news, CFO Molly Henderson sold 6,307 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $7.75, for a total value of $48,879.25. Following the completion of the transaction, the chief financial officer now owns 98,698 shares of the company’s stock, valued at $764,909.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Molly Henderson sold 6,307 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $7.75, for a total value of $48,879.25. Following the completion of the transaction, the chief financial officer now owns 98,698 shares of the company’s stock, valued at $764,909.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the firm’s stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the completion of the transaction, the insider now directly owns 3,755,583 shares of the company’s stock, valued at approximately $30,420,222.30. The disclosure for this sale can be found here. Insiders sold a total of 3,730,296 shares of company stock worth $30,240,515 over the last three months. Insiders own 7.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a “buy” rating and issued a $26.00 price objective on shares of Phathom Pharmaceuticals in a report on Thursday, April 11th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.